Comparison between 99mTc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy

American Journal of Roentgenology

Volumn 200, Issue 3, 2013, Pages

  Minutoli, Fabio ^a   Di Bella, Gianluca ^a   Mazzeo, Anna ^a   Donato, Rocco ^a   Russo, Massimo ^a   Scribano, Emanuele ^a   Baldari, Sergio ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

99mTc diphosphonate scintigraphy; Cardiac amyloidosis; Late gadolinium enhancement; MRI; Transthyretin familial amyloid polyneuropathy

Indexed keywords

ETIDRONIC ACID TC 99M; GADOBUTROL; GADOLINIUM; PREALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM DERIVATIVE; TECHNETIUM TC 99M DIPHOSPHONATE;

ADULT; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG UPTAKE; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GAMMA CAMERA; HEART ATRIUM; HEART DISEASE; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; ULTRASOUND SCANNER; AGED; CARDIOMYOPATHY; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; DIPHOSPHONATES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; OBSERVER VARIATION; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM COMPOUNDS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

MLCS; MLOWN;

EID: 84876115445     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.8737     Document Type: Article

References (35)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898-909
2. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000; 45:107-137
3. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006; 166:1805-1813
4. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol 2001; 248:647-657
5. Ando Y, Nakamura M, Araki S. Transthyretinrelated familial amyloidotic polyneuropathy. Arch Neurol 2005; 62:1057-1062
6. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120:1203-1212
7. Puille M, Altland K, Linke RP, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002; 29:376-379
8. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2- propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46:1076-1084
9. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011; 38:470-478
10. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011; 4:659-670
11. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111:186-193
12. Maceira AM, Prasad SK, Hawkins PN, Roughton N, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10:54
13. vanden Driesen RI, Slaughter RE, Strugnell WE. MR findings in cardiac amyloidosis. AJR 2006; 186:1682-1685
14. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: non invasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51:1022-1030
15. Di Bella G, Minutoli F, Mazzeo A, et al. MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. AJR 2010; 195:1313; [web] W394-W399
16. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3:155-164
17. Mekinian A, Lions C, Leleu X, et al Lille Amyloidosis Study Group. Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. Am J Med 2010; 123:864-868
18. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367
19. Cerqueira MD, Weissman NJ, Dilsizian V, et al American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539-542
20. Schober O, Rahbar K, Riemann B. Multimodality molecular imaging: from target description to clinical studies. Eur J Nucl Med Mol Imaging 2009; 36:302-314
21. Kono AK, Yamada N, Higashi M, et al. Dynamic late gadolinium enhancement simply quantified using myocardium to lumen signal ratio: normal range of ratio and diffuse abnormal enhancement of cardiac amyloidosis. J Magn Reson Imaging 2011; 34:50-55
22. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006; 92:343-349
23. Smith TJ, Kyle R, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984; 59:547-555
24. Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med 2005; 118:1287
25. Hosch W, Kristen AV, Libicher M, et al. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid 2008; 15:196-204
26. Jellis C, Martin J, Narula J, Marwick TH. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010; 56:89-97
27. Messroghli DR, Greiser A, Frölich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007; 26:1081-1086
28. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008; 52:1574-1580
29. Sueyoshi E, Sakamoto I, Uetani M. Contrast-en-hanced myocardial inversion time at the null point for detection of left ventricular myocardial fibrosis in patients with dilated and hypertrophic cardiomyopathy: a pilot study. AJR 2010; 194:945; [web]W293-W298
30. Han Y, Peters DC, Dokhan B, Manning WJ. A shorter difference between myocardium and blood optimal inversion time suggests diffuse fibrosis in dilated cardiomyopathy. J Magn Reson Imaging 2009; 30:967-972
31. Aquaro GD, Positano V, Pingitore A, et al. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2010; 12:21
32. Schelbert EB, Hsu LY, Anderson SA, et al. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. Circ Cardiovasc Imaging 2010; 3:743-752
33. Desai MY, Gupta S, Bomma C, et al. The apparent inversion time for optimal delayed enhancement magnetic resonance imaging differs between the right and left ventricles. J Cardiovasc Magn Reson 2005; 7:475-479
34. Grosse-Wortmann L, Macgowan CK, Vidarsson L, Yoo SJ. Late gadolinium enhancement of the right ventricular myocardium: is it really different from the left? J Cardiovasc Magn Reson 2008; 10:20-28
35. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79:319-328